Emerging synthetic drugs for the management of Hidradenitis Suppurativa: a comprehensive update - PubMed
5 hours ago
- #Synthetic Drugs
- #Inflammatory Skin Disease
- #Hidradenitis Suppurativa
- Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder with limited approved biologics, leading to a need for new synthetic drugs.
- Emerging oral synthetic drugs for HS include JAK inhibitors (e.g., povorcitinib, upadacitinib), TYK2 inhibitors (e.g., brepocitinib), PDE-4 inhibitors (e.g., apremilast), BTK/SYK inhibitors (e.g., remibrutinib), IRAK-4 inhibitors (zimlovisertib), and HSP-90 inhibitors (RGRN-305).
- Expert opinion highlights JAK1 inhibition as the most advanced small-molecule strategy, with topical JAK inhibitors for milder HS and BTK inhibitors in Phase 3 trials, emphasizing personalized treatment based on comorbidities and biomarkers.